Conditions: Branch Retinal Vein Occlusion Central Retinal Vein Occlusion Macular Edema
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 14
Healthy volunteers: no

Brief summary:
This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular edema secondary to retinal vein occlusion in patients that have previously failed treatment with other macular edema treatments including bevacizumab.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: ranibizumab 0.5mg intervention 2: ranibizumab 1.0mg
Intervention descriptions: intervention 1: Standard dose intervention 2: High dose

Protocol document: